Form 4: Evoke Pharma's Chief Medical Officer, Marilyn R. Carlson, Reports Stock Option Grant

Marilyn R. Carlson, Chief Medical Officer of Evoke Pharma, reports the acquisition of stock options.

Summary

• Marilyn R. Carlson, the Chief Medical Officer of Evoke Pharma Inc. (EVOK), filed a Form 4 on August 8, 2024, reporting a transaction.
• On August 7, 2024, Carlson acquired stock options for 17,291 shares of Evoke Pharma's common stock at an exercise price of $5.27.
• These options vest monthly, with 1/36th of the total shares vesting on each monthly anniversary of August 7, 2024, contingent upon continuous service, and will be fully vested on the third anniversary of the Vesting Commencement Date (August 7, 2027).

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and suggests confidence in the company's future performance, but it's not a major event.

Positives

• The granting of stock options to the Chief Medical Officer aligns her interests with those of the shareholders, incentivizing her to contribute to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially benefit shareholders if the company's stock price increases due to the executive's incentivized performance.

Key Dates

Keywords

Evoke Pharma, Stock Options, Form 4, Marilyn R. Carlson, Chief Medical Officer, Beneficial Ownership, EVOK